IMS Health should have free cash flows this year of over $340 million (the actual number should be higher than $400 million, but is benefited by a $60 million onetime tax benefit).

Global prescription sales growth of generics drugs slowed to 3.6 percent in the twelve months ending September 2008, down from 11.4 percent in 2007, a ...

The UK Competition Commission has provisionally decided not to remove or vary current restrictions on how IMS Health sells its specialised pharmaceutical data services.

PARSIPPANY, N.J. — U.S. spending on drugs grew 2.3% to $307.4 billion in 2010, according to a new report by the IMS Institute for Healthcare Informatics, part of industry research firm IMS Health.